GSK Earnings Call Highlights Specialty Strength, H2 Upside

GlaxoSmithKline ((GSK)) has held its Q1 earnings call. Read on for the main highlights of the call.

GlaxoSmithKline’s latest earnings call struck an upbeat tone, with management emphasizing broad‑based momentum in specialty medicines, vaccines and late‑stage R&D, even as legacy general medicines and some launch frictions posed headwinds. Executives framed 2026 as a year of profitable growth, but one where much of the upside will arrive in the second half.

Broad-Based Top-Line Growth

GSK reported first-quarter sales rising 5% to more than GBP 7.6 billion, underscoring solid demand across key franchises. Management highlighted that this growth came despite pressure in older general medicines, underscoring the shift toward higher‑value specialty products.

Specialty Medicines Drive Performance

Specialty medicines grew 14% in the quarter and were described as the main engine of the group’s top-line expansion. This mix shift toward specialty therapies is also helping profitability, as newer, high-margin products take a larger share of sales.

Shingrix Delivers Record Quarter

Shingrix posted record quarterly revenue of more than GBP 1 billion, up 20% year on year, powered by strong vaccination programs. Europe led with 51% growth while the U.S. advanced 12%, although management cautioned that stocking and program timing will make comparisons tougher later in the year.

Margin Expansion and EPS Growth

Core operating profit grew 10%, outpacing sales, while earnings per share rose 9%, helped by a favorable product mix and legal settlement benefits. Executives stressed that underlying profit progression remains healthy even as spending rises to support the pipeline.

Cash Generation and Balance Sheet Strength

The company generated GBP 1.4 billion of cash in the quarter, supporting a net debt level of 1.4 times EBITDA and ongoing shareholder returns. Free cash flow was boosted by a special ViiV dividend, and the share buyback remains on track, signaling confidence in balance‑sheet resilience.

HIV Franchise Maintains Strong Momentum

HIV sales increased 10% overall, with the U.S. up 15%, driven by long-acting regimens Cabenuva and Apretude, which grew 31% and 44% respectively. Management noted that about 79% of U.S. switches are coming from competitor products, underscoring share gains, though state-level reimbursement moves remain a watch point.

Nucala’s COPD Expansion Builds Scale

Nucala delivered double-digit growth after its expansion into U.S. COPD, with new patient starts up 65% year on year and around 45% COPD share in that market. Early uptake in China is also encouraging, with roughly half of new COPD patients starting on the drug, despite high churn in the biologic respiratory space.

Oncology Pipeline and Commercial Wins

In oncology, Jemperli revenue climbed 40% to GBP 232 million, backed by RUBY data showing a substantial survival benefit in certain endometrial cancers. Early data for Mo‑Rez and Ris‑Rez combinations showed promising response rates and progression‑free survival, though antibody‑drug conjugate safety, including ILD monitoring, remains under close scrutiny.

Bepirovirsen’s Breakthrough in Hepatitis B

Positive Phase III results for bepirovirsen in chronic hepatitis B support its potential as a functional cure, with U.S. and China regulators granting expedited reviews. Management flagged, however, that limited testing and under‑diagnosis globally could temper the speed of commercial uptake even if approvals come through.

R&D Acceleration and Bolt-On Deals

GSK is accelerating its late-stage pipeline, with seven Phase III starts slated for 2025 and ten more in 2026, alongside pivotal trials for key assets like Ris‑Rez, Mo‑Rez and velzatinib. The company is also leaning into business development, closing the 35Pharma deal and agreeing to acquire RAPT Therapeutics, reinforcing its long-term growth story.

Pressure in General Medicines

General Medicines sales declined 6%, reflecting ongoing erosion in older established products that are losing relevance and pricing power. Management reiterated that the portfolio’s growth prospects now hinge on newer assets, with meaningful improvement expected only later in the year.

Trelegy and Payer Headwinds

Trelegy’s growth was constrained by higher U.S. co‑pay requirements tied to Medicare redesign, a dynamic that was particularly visible in the first quarter. Executives expect these pressures and tough comparisons to weigh on the second quarter before trends improve in the back half.

Shingrix Phasing and Inventory Effects

The company cautioned that Shingrix’s standout quarter was helped by U.S. prefilled-syringe stocking and annualization of programs in Europe and Japan. Modest inventory build at wholesalers and retailers means underlying demand may look softer against these elevated baselines later this year.

Exdensur Access Delays Uptake

Exdensur’s U.S. launch is being held back by limited market access before a key reimbursement code becomes effective in early July, with only about 20% of commercial patients currently covered. Management cited strong patient preference for six-monthly dosing but acknowledged that broader uptake will lag until access improves.

Adoption Challenges for Bepirovirsen

While bepirovirsen’s clinical profile appears compelling, limited hepatitis B surface antigen testing and under-diagnosis in large markets like China pose a commercial hurdle. GSK signaled that significant effort will be needed to expand screening and diagnosis to unlock the drug’s full revenue potential.

Higher R&D Spend and Financial Offsets

R&D expenses are rising as the company funds pivotal trials for candidates such as efimosfermin and velzatinib to accelerate growth beyond the current decade. Some of this additional spending, alongside higher taxes and finance costs, partially offset EPS gains, underscoring the delicate balance between investing and delivering near-term earnings.

Risks in ADC Safety and Market Access

Management discussed hematologic toxicities and instances of treatment-related lung inflammation observed in partner ADC studies, stressing the focus on monitoring and risk management. They also flagged evolving state-level reimbursement policies, exemplified by changes in HIV assistance programs, as a continuing risk factor for the franchise.

Currency and Working-Capital Effects

Despite strong underlying cash generation, the reported figure was dampened somewhat by currency movements and timing shifts in trade payables. The company indicated that these effects should normalize, with a larger share of cash inflow expected in the second half.

Guidance and Outlook Remain Intact

GSK reaffirmed its February guidance for another year of profitable growth, with most product group and profit expansion skewed to the second half as phasing effects unwind. The company expects more than GBP 10 billion of cash generation from operations this year, continued disciplined deal-making, further net‑debt reduction and ongoing dividends and buybacks.

The earnings call painted a picture of a company successfully pivoting toward higher-growth, higher-margin assets while managing legacy and reimbursement headwinds. For investors, the message was clear: near-term results are solid, the pipeline is advancing quickly, and the bulk of 2026’s upside should become visible as the year progresses.